Biocartis Idylla BRAF Mutation Test - HSA Registration DE0019387
Access comprehensive regulatory information for Biocartis Idylla BRAF Mutation Test in the Singapore medical device market through Pure Global AI's free database. This CLASS C IVD medical device is registered under HSA registration number DE0019387 and owned by Biocartis NV. The device was registered on July 05, 2017.
This page provides complete registration details including product owner information, registrant details, importer information, and regulatory compliance data from the official Singapore HSA medical device database. Pure Global AI offers free access to Singapore's complete medical device registry, helping global MedTech companies navigate HSA regulations efficiently.
The Idylla™ BRAF Mutation Test, performed on the Biocartis Idylla™ System, is an in vitro diagnostic Test for the qualitative detection of V600E/E2/D and V600K/R/M mutations in codon 600 of the BRAF gene. The Idylla™ BRAF Mutation Test uses DNA liberated from formalin-fixed paraffin-embedded (FFPE) tissue sections from human melanoma tumor cells. The Test is a sample-to-result real-time PCR. The results of the Idylla™ BRAF Mutation Test may be useful for the physician to aid in identifying metastatic melanoma patients who may benefit from BRAF targeted therapy. The Idylla™ BRAF Mutation Test is not intended to diagnose metastatic melanoma. The physician shall take other disease factors into account, other than the patient’s mutation status, to make a therapy decision.